A single dose of MM120 (lysergide D-tartrate) reduces anxiety in a dose-dependent way in adults with moderate to severe generalized anxiety disorder. In a phase 2b randomized, double-blind, placebo-controlled trial with 198 participants, the 100-µg and 200-µg doses produced significantly greater reductions in Hamilton Anxiety Rating Scale scores at 4 weeks than placebo, with differences of -5.0 and -6.0 points, respectively. Lower doses (25 µg and 50 µg) did not differ from placebo. Common side effects included visual perceptual changes and nausea, which increased with dose.
A proof-of-concept study tested the MindMed Session Monitoring System (MSMS), a continuous passive monitoring system designed for use during treatment sessions with consciousness-altering drugs. Participants completed 129 Spravato sessions with MSMS at an outpatient psychiatry clinic. Results indicated high rates of data quality and self-reported usability among both participants and healthcare providers. These findings suggest that such systems could assist with patient monitoring during consciousness-altering treatments, potentially reducing the burden on providers and improving accessibility.